Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 3Phase 3 1Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 6Breast 3

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1

Interventions

Trastuzumab 72Paclitaxel 63Cyclophosphamide 56pembrolizumab 52Fulvestrant 42Carboplatin 39Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 20Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × bicalutamide × Breast × Clear all
NCT05095207 2026-04-13

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Recruiting
42 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03090165 2026-01-02

Ribociclib and Bicalutamide in AR+ TNBC

Big Ten Cancer Research Consortium

Phase 1/2 Active not recruiting
37 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02605486 2025-07-03

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
46 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡